RVL Pharmaceuticals plc (RVLPQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (900.00%)
Jan 24, 2025, 4:00 PM EDT
RVL Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2016 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2016 - 2017 |
| Revenue | 49.72 | 17.5 | 27.76 | 240.03 | 263.7 | Upgrade
|
| Revenue Growth (YoY) | 184.10% | -36.96% | -88.43% | -8.98% | 7.31% | Upgrade
|
| Cost of Revenue | 6.66 | 3.12 | 3.29 | 111.63 | 140.08 | Upgrade
|
| Gross Profit | 43.07 | 14.38 | 24.47 | 128.4 | 123.62 | Upgrade
|
| Selling, General & Admin | 79.08 | 83.99 | 72.93 | 93.17 | 74.44 | Upgrade
|
| Research & Development | 3.97 | 5.7 | 13.28 | 32.18 | 43.49 | Upgrade
|
| Operating Expenses | 83.05 | 89.69 | 86.21 | 125.35 | 117.94 | Upgrade
|
| Operating Income | -39.98 | -75.31 | -61.74 | 3.05 | 5.68 | Upgrade
|
| Interest Expense | -3.11 | -3.04 | -4.09 | -18.21 | -20.79 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.53 | 5.54 | -0.05 | 0.88 | 0.66 | Upgrade
|
| EBT Excluding Unusual Items | -35.56 | -72.81 | -65.89 | -14.28 | -14.44 | Upgrade
|
| Merger & Restructuring Charges | -2.9 | -6 | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -86.32 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 5.64 | - | - | - | Upgrade
|
| Asset Writedown | -13.31 | -7.88 | -28.91 | -283.75 | -17.9 | Upgrade
|
| Other Unusual Items | 0.06 | -1.48 | - | - | - | Upgrade
|
| Pretax Income | -51.71 | -82.53 | -94.8 | -298.02 | -118.66 | Upgrade
|
| Income Tax Expense | -0.02 | 0.32 | -5.78 | -27.12 | -8.98 | Upgrade
|
| Earnings From Continuing Operations | -51.69 | -82.85 | -89.01 | -270.9 | -109.68 | Upgrade
|
| Earnings From Discontinued Operations | - | 17.93 | 9.42 | - | - | Upgrade
|
| Net Income | -51.69 | -64.92 | -79.59 | -270.9 | -109.68 | Upgrade
|
| Net Income to Common | -51.69 | -64.92 | -79.59 | -270.9 | -109.68 | Upgrade
|
| Shares Outstanding (Basic) | 90 | 67 | 61 | 52 | 45 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 67 | 61 | 52 | 45 | Upgrade
|
| Shares Change (YoY) | 33.32% | 11.05% | 15.82% | 15.66% | 5.65% | Upgrade
|
| EPS (Basic) | -0.58 | -0.96 | -1.31 | -5.17 | -2.42 | Upgrade
|
| EPS (Diluted) | -0.58 | -0.96 | -1.31 | -5.17 | -2.42 | Upgrade
|
| Free Cash Flow | -38.56 | -56.51 | 14.67 | 29.6 | 33.41 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.84 | 0.24 | 0.56 | 0.74 | Upgrade
|
| Gross Margin | 86.61% | 82.18% | 88.14% | 53.49% | 46.88% | Upgrade
|
| Operating Margin | -80.41% | -430.32% | -222.40% | 1.27% | 2.15% | Upgrade
|
| Profit Margin | -103.96% | -370.95% | -286.68% | -112.86% | -41.59% | Upgrade
|
| Free Cash Flow Margin | -77.56% | -322.92% | 52.84% | 12.33% | 12.67% | Upgrade
|
| EBITDA | -39.61 | -67.14 | -40.72 | 54.1 | 77.36 | Upgrade
|
| EBITDA Margin | -79.65% | - | -146.66% | 22.54% | 29.34% | Upgrade
|
| D&A For EBITDA | 0.38 | 8.18 | 21.03 | 51.05 | 71.68 | Upgrade
|
| EBIT | -39.98 | -75.31 | -61.74 | 3.05 | 5.68 | Upgrade
|
| EBIT Margin | -80.41% | - | -222.40% | 1.27% | 2.15% | Upgrade
|
| Revenue as Reported | 49.72 | 17.5 | 27.76 | 240.03 | 263.7 | Upgrade
|
| Advertising Expenses | 15.9 | 14.9 | 6.8 | 8.5 | 6.2 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.